P2RY12 and chronic obstructive pulmonary disease: TA was significantly more often used in the AMI and STEMI groups of patients treated with the third generation of P2Y12 inhibitors compared to older patients, smokers, with COPD, those treated with bivalirudin, non-diabetics, and with greater body mass.